iQue® High-Throughput Screening (HTS) by Cytometry’s Post

Biosimilars offer a lower cost alternative to approved biotherapeutics. Comprehensive comparability studies with orthogonal analysis using ligand binding kinetics and live-cell binding can further reinforce confidence in biosimilarity. Read more in our latest white paper: https://ow.ly/jbt550SzllT #biosimilars #ligandbinding #kinetics #livecellanalysis #biotherapeutics

Biosimilars offer a lower cost alternative to approved biotherapeutics. Comprehensive comparability studies with orthogonal analysis using ligand binding kinetics and live-cell binding can further reinforce confidence in biosimilarity. Read more in our latest white paper: https://ow.ly/VLrz50SzljS #biosimilars #ligandbinding #kinetics #livecellanalysis #biotherapeutics

Interested in Analytical Characterization of Biosimilars During Development? Orthogonal Analysis Using Ligand Binding Kinetics & Live Cell Binding https://lnkd.in/gbaceYJ2 #biosimilars #ligandbinding #kinetics #livecellanalysis #biotherapeutics

Visit us at booth #52, Sanofi Global Analytical Symposium in Cambridge, MA, from June 11-12 and learn about Gator next generation of BLI technology! #GatorBio #GatorBLI #BiolayerInterferometry #BLI #Quantitation #AntibodyDiscovery #Biotherapeutics #AntibodyTherapeutics #DrugDiscovery #EpitopeBinning #Kinetics #ProteinAnalysis

How do bioactive products like those offered at Biostone Biologics benefit bone grafting? Bioactive products in bone grafting can help enhance the healing process and improve the success rate of the procedure. Here are some benefits: 1. Promoting Bone Regeneration: Bioactive products contain substances that stimulate bone growth and regeneration, leading to faster healing and integration of the graft material with the surrounding bone. 2. Reducing Healing Time: These products can expedite the healing process by promoting the growth of new bone tissue at the graft site. 3. Enhancing Graft Stability: Bioactive materials can enhance the stability and strength of the graft by facilitating the formation of a strong bond between the graft material and the existing bone. 4. Reducing Risk of Complications: By accelerating healing and improving integration, bioactive products can help reduce the risk of complications such as graft rejection or infection. 5. Improving Long-term Success: Ultimately, the use of bioactive products in bone grafting can improve the long-term success of the procedure by creating a more stable and functional structure at the graft site. Overall, bioactive products play a crucial role in improving the outcomes of bone grafting procedures by enhancing bone regeneration, reducing healing time, increasing graft stability, lowering complication risks, and ensuring long-term success. #biologics #synthetics #medicaldevice #dentalimplants #veterenarianimplants #spinalimplants #orthopedicimplants #footandankle #extremities

For those interested in Physiologically Based Biopharmaceutics Modeling (PBBM) please check out our recently published article from the 2023 PBBM workshop. It proposes best practices for measuring solubility, dissolution, precipitation and permeability for parameterizing PBBMs, summarizes breakout sessions, and shares PBBM case studies. https://lnkd.in/gda_HH4F

If you want to implement the MAT, this workshop may be of interest to you👇

For those of you who work with disaccharides this paper by professor Jan Swenson and his group might be of a high interest. It is a bit different work from what, at least, I usually read when it concerns #sucrose and #trehalose. #pharmaceutics #cosmetics #preservatives https://lnkd.in/dFdG-EPs

𝗙𝗲𝘅𝗼𝗳𝗲𝗻𝗮𝗱𝗶𝗻𝗲-𝗹𝗼𝗮𝗱𝗲𝗱 𝗰𝗵𝗶𝘁𝗼𝘀𝗮𝗻 𝗰𝗼𝗮𝘁𝗲𝗱 𝘀𝗼𝗹𝗶𝗱 𝗹𝗶𝗽𝗶𝗱 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 (𝗦𝗟𝗡𝘀): 𝗔 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗿𝗮𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝘂𝗹𝗰𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗰𝗼𝗹𝗶𝘁𝗶𝘀 The targeting and mucoadhesive features of chitosan (CS)-linked solid lipid nanoparticles (SLNs) were exploited to efficiently deliver fexofenadine (FEX) into the colon, forming a novel and potential oral therapeutic option for ulcerative colitis (UC) treatment. Different FEX-CS-SLNs with varied molecular weights of CS were prepared and optimized. Optimized FEX-CS-SLNs exhibited 229 ± 6.08 nm nanometric size, 36.3 ± 3.18 mV zeta potential, 64.9 % EE, and a controlled release profile. FTIR, DSC, and TEM confirmed good drug entrapment and spherical particles. Mucoadhesive properties of FEX-CS-SLNs were investigated through mucin incubation and exhibited considerable mucoadhesion. The protective effect of FEX-pure, FEX-market, and FEX-CS-SLNs against acetic acid-induced ulcerative colitis in rats was examined. Learn more here: https://lnkd.in/ezerwXtz #sln #excipients #drugdelivery

𝗦𝗼𝗹𝘂𝗽𝗹𝘂𝘀® 𝗻𝗮𝗻𝗼𝗺𝗶𝗰𝗲𝗹𝗹𝗲𝘀 𝗲𝗻𝗵𝗮𝗻𝗰𝗲 𝗜𝗴𝗚 𝗻𝗲𝘂𝘁𝗿𝗮𝗹𝗶𝘇𝗶𝗻𝗴 𝗽𝗿𝗼𝗽𝗲𝗿𝘁𝗶𝗲𝘀 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗦𝗵𝗶𝗴𝗮 𝘁𝗼𝘅𝗶𝗻 𝘁𝘆𝗽𝗲 𝟮 Shiga toxin (Stx) is the main virulence factor of Stx-producing Escherichia coli, a pathogen responsible for developing Hemolytic Uremic Syndrome. Nowadays, no specific treatment exists for this disease, and nanomicelles may be an excellent platform for the delivery of specific compounds, including immunoglobulins (IgG), for therapeutic or diagnostic strategies. In this work, Soluplus® nanomicelles (NM) were associated with IgG against Stx type 2 (NM-IgG-Stx2). Physicochemical evaluation of NM-IgG-Stx2 was performed by Dynamic Light Scattering, Uv–Vis, Fluorescence, and Circular Dichroism spectroscopy. Read more here: https://lnkd.in/eaGNsKmC #excipents #soluplus #drugdelivery BASF Pharma Solutions